BIOS

The company's core business involves creating a platform that can interpret and modulate the human nervous system's signals in real-time. This technology is designed to identify neural biomarkers, which are specific nerve activity patterns linked to health conditions. By understanding this "neural code," BIOS aims to develop a new class of personalized medicines for chronic diseases such as cardiac conditions, hypertension, diabetes, and rheumatoid arthritis. The business model is centered on partnerships with pharmaceutical companies and medical device manufacturers, offering them its AI-driven neural insights platform to accelerate drug discovery and clinical trials. This can reduce the time to assess a drug's efficacy on the nervous system from months to minutes.

Initially known as Cambridge Bio-Augmentation Systems (CBAS) with a focus on prosthetic interfaces, the company has since shifted its focus to its AI platform that can integrate with various medical devices. A significant milestone for BIOS Health was its selection by the US National Institutes of Health (NIH) to provide the core technology for the REVEAL project, the largest-ever clinical study of human neural data. The company has secured over $26 million in funding through multiple rounds, including support from Y Combinator, Real Ventures, and Selvedge Venture. To support its growth and commercialization, BIOS has established an AI and neuroscience research site in Montreal, Canada, and a precision medicine center in California, US.